报价延迟最少15分钟:2026/03/09 16:39 EDT
盘后时段
|
||||
|
34.08 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
34.08
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.12/2.96
|
|
企业价值
17.82B
|
| 资产负债 |
|
每股账面净值
13.04
|
| 现金流量 |
|
现金流量率
0.08
|
| 损益表 |
|
收益
5.81B
|
|
每股收益
12.60
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder. |
